Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
about
Synthetic lethality in lung cancer and translation to clinical therapiesEngineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivoTargeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyNanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations.Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomesCombination drug delivery approaches in metastatic breast cancerTumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancerVitamin C-driven epirubicin loading into liposomes.TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies.Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity.Cancer nanomedicine: progress, challenges and opportunities.Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.Development of stealth liposome coencapsulating doxorubicin and fluoxetine.Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.The Role of Magnesium Supplementation in Cisplatin-induced Nephrotoxicity in a Rat Model: No Nephroprotectant Effect.Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro.Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer.In vivo and in vitro studies of Cry5B and nicotinic acetylcholine receptor agonist anthelmintics reveal a powerful and unique combination therapy against intestinal nematode parasitesSimultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
P2860
Q28072904-0A64AE26-FE04-42DD-A45E-337622F13A09Q28073956-7031260A-DC2E-4AB5-9325-8455930E7F55Q28476362-C81A698D-A929-4279-8813-A3DB99D6B502Q30279055-D8B67022-9B19-4721-BD03-183A19079C3BQ33859472-065A105D-25B5-488E-AA5C-C4A37193D653Q34479313-66A4521A-FEDE-4128-B4EF-C993C315CE7DQ34693012-DC754784-BAE3-4AB1-89E7-4F18C169840EQ35569028-ACCE8444-C2F5-4E12-A467-B2583A2A291FQ35692141-955D8E38-743A-4BAE-A5DD-1C86D2B457A9Q35826566-BD02F65B-7FCD-456D-A7FF-F385FC732189Q35955198-EDBB3FEE-834A-4D79-871B-4A3FBD819F77Q36303474-C458ADD3-DD5D-4AAC-8032-D29A6FE63415Q37216027-07DDF705-DEF7-4AF6-843E-A3B15422AA34Q37620658-3C052AF2-3E6B-48E1-BF2E-A1C11718063CQ37813687-CDEE9320-AA6D-4AAB-8870-9E4873E6B788Q37955222-58879C4C-5B24-4AE9-BE32-6396F982E292Q38058785-5283EFF1-90A0-4A88-9229-515D3FD5D8CCQ38183852-0E1AF421-5A0B-46B5-BF61-A25C06C71D7DQ38854876-1FD9953E-FFC4-4BD9-8D37-0A9470054A4CQ38869805-4526381F-6B59-409C-857B-35F52A1B5A91Q38958186-1A4FDC25-F7E7-4A84-9608-C35427C459EFQ39005226-C961BD94-D807-4A54-B5EF-0B27281D359FQ39257622-7E0D5CD8-E1C8-4F0D-A44F-102D54C2B422Q39608885-CA894F58-22F0-4733-87C8-204C406C8A56Q40009120-C735033D-4CD2-4C67-91E0-31871CDCFECDQ41514180-FC278F5A-D633-43A3-9FEF-F143FCC46F2EQ41879041-05D138C1-E4F4-4F45-B558-80A4D7C2F54FQ41914702-789148B6-C8F3-4990-B223-DBCC76248574Q41967128-267E9737-2EDD-489D-939F-A875BFA2E0A7Q42562347-4BE803F6-20FE-4FF9-A91F-8E5305884E78Q43203991-A1CFA8A2-E575-42AB-8FE0-24632B79006DQ51734368-F3FBE5B1-F23A-41D1-B1E1-0083A28B0F57Q54157122-F5E81D03-2396-4710-B162-03420FDDE875Q55504427-573260FC-B15A-42D9-B702-C1B9969F7DB1
P2860
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Drug ratio-dependent antitumor ...... inations in vitro and in vivo.
@en
Drug ratio-dependent antitumor ...... inations in vitro and in vivo.
@nl
type
label
Drug ratio-dependent antitumor ...... inations in vitro and in vivo.
@en
Drug ratio-dependent antitumor ...... inations in vitro and in vivo.
@nl
prefLabel
Drug ratio-dependent antitumor ...... inations in vitro and in vivo.
@en
Drug ratio-dependent antitumor ...... inations in vitro and in vivo.
@nl
P2093
P1476
Drug ratio-dependent antitumor ...... binations in vitro and in vivo
@en
P2093
Alan W Tsang
Lawrence D Mayer
Nancy Dos Santos
Natalia Zisman
Paul G Tardi
Sharon A Johnstone
Troy O Harasym
P304
P356
10.1158/1535-7163.MCT-09-0243
P577
2009-08-11T00:00:00Z